134 related articles for article (PubMed ID: 33860919)
1. Comment on: "Safety of Marketed Cancer Supportive Care Biosimilars in the U.S.: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database".
Putzke J; Haughie S; Zou KH; Ranganna GM
BioDrugs; 2021 May; 35(3):373-374. PubMed ID: 33860919
[No Abstract] [Full Text] [Related]
2. Author's Reply to Joerg Putzke et al. Comment on: "Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database".
Qian J; Truong CB; Tanni KA
BioDrugs; 2021 May; 35(3):375-377. PubMed ID: 33860920
[No Abstract] [Full Text] [Related]
3. Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Tanni KA; Truong CB; Almahasis S; Qian J
BioDrugs; 2021 Mar; 35(2):239-254. PubMed ID: 33439472
[TBL] [Abstract][Full Text] [Related]
4. Nomenclature and traceability debate for biosimilars: small-molecule surrogates lend support for distinguishable nonproprietary names.
Chao J; Skup M; Alexander E; Tundia N; Macaulay D; Wu E; Mulani P
Adv Ther; 2015 Mar; 32(3):270-83. PubMed ID: 25772256
[TBL] [Abstract][Full Text] [Related]
5. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
6. Adverse event reporting of marketed biosimilar and biological monoclonal antibody cancer treatments in the United States.
Xue X; Truong B; Qian J
Expert Opin Biol Ther; 2023; 23(8):841-849. PubMed ID: 36892184
[TBL] [Abstract][Full Text] [Related]
7. Hypnotics and infections: disproportionality analysis of the U.S. Food & Drug Administration adverse event reporting system database.
Meng L; Huang J; He Q; Zhao Y; Zhao W; Tan J; Sun S; Yang J
J Clin Sleep Med; 2022 Sep; 18(9):2229-2235. PubMed ID: 35713182
[TBL] [Abstract][Full Text] [Related]
8. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
[TBL] [Abstract][Full Text] [Related]
9. Evaluating AE Reporting of Two Off-Patent Biologics to Inform Future Biosimilar Naming and Reporting Practices.
Stergiopoulos S; Getz K
Drug Saf; 2015 Aug; 38(8):687-92. PubMed ID: 26108298
[TBL] [Abstract][Full Text] [Related]
10. More extreme duplication in the U.S. FDA FAERS database and a suggested check point for disproportionality analysis.
Hauben M; Zou C; Bright S; Hung E
Pharmacoepidemiol Drug Saf; 2021 Aug; 30(8):1140-1141. PubMed ID: 33960586
[No Abstract] [Full Text] [Related]
11. Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS).
Rahman MM; Alatawi Y; Cheng N; Qian J; Peissig PL; Berg RL; Page DC; Hansen RA
Clin Drug Investig; 2017 Dec; 37(12):1143-1152. PubMed ID: 28933038
[TBL] [Abstract][Full Text] [Related]
12. Safety of marketed biosimilar monoclonal antibody cancer treatments in the US: a disproportionality analysis using the food and drug administration adverse event reporting system (FAERS) database.
Xue X; Qian J
Expert Opin Drug Saf; 2024 May; ():1-10. PubMed ID: 38680112
[TBL] [Abstract][Full Text] [Related]
13. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
[TBL] [Abstract][Full Text] [Related]
14. Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase
Vogel U; van Stekelenborg J; Dreyfus B; Garg A; Habib M; Hosain R; Wisniewski A
Drug Saf; 2020 Apr; 43(4):351-362. PubMed ID: 32020559
[TBL] [Abstract][Full Text] [Related]
15. Filing Sources after Oral P2Y12 Platelet Inhibitors to the Food and Drug Administration Adverse Event Reporting System (FAERS).
Serebruany VL; Cherepanov V; Kim MH; Litvinov O; Cabrera-Fuentes HA; Marciniak TA
Cardiology; 2017; 138(4):249-253. PubMed ID: 28898876
[TBL] [Abstract][Full Text] [Related]
16. Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems.
Raschi E; Girardi A; Poluzzi E; Forcesi E; Menniti-Ippolito F; Mazzanti G; De Ponti F
Drug Saf; 2018 Aug; 41(8):745-752. PubMed ID: 29582393
[TBL] [Abstract][Full Text] [Related]
17. Comment on: "A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)".
Noguchi Y
Drug Saf; 2022 Dec; 45(12):1551-1552. PubMed ID: 36223038
[No Abstract] [Full Text] [Related]
18. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.
Raschi E; Poluzzi E; Koci A; Salvo F; Pariente A; Biselli M; Moretti U; Moore N; De Ponti F
Br J Clin Pharmacol; 2015 Aug; 80(2):285-93. PubMed ID: 25689417
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of adverse events associated with filgrastim originator and biosimilar using a spontaneous reporting system database.
Niinomi I; Hosohata K; Oyama S; Inada A; Wakabayashi T; Iwanaga K
Pharmazie; 2020 Apr; 75(4):151-153. PubMed ID: 32295692
[TBL] [Abstract][Full Text] [Related]
20. Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS).
Wittayanukorn S; Qian J; Johnson BS; Hansen RA
J Oncol Pharm Pract; 2017 Mar; 23(2):93-102. PubMed ID: 26661047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
